AEON Biopharma Investor Relations Material
Latest events
Q1 2025
14 May, 2025
Q4 2024
24 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AEON Biopharma Inc
Access all reports
AEON Biopharma Inc. is a biopharmaceutical company focused on the development of therapeutic applications for botulinum toxin. The company aims to advance treatments for a range of medical conditions, particularly in neurology and related therapeutic areas. AEON Biopharma is engaged in clinical research and regulatory processes to expand the use of botulinum toxin beyond aesthetic applications. The company is headquartered in Irvine, California, and its shares are listed on the NYSE.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
AEON
Country
🇺🇸 United States